Abstract 298P
Background
Adenoid cystic carcinoma (ACC) of the breast is a rare subtype of breast cancer that is characterized by more favorable outcomes than extramammary ACC. Its rarity makes the establishment of standardized treatment protocols challenging. This study aimed to develop a machine learning (ML)-based prognostic model that improves the accuracy of survival rate predictions for patients with ACC.
Methods
The SEER database provided the data used for this study’s analysis (2000–2020). Patients who met any of the following criteria were excluded: diagnosis not confirmed by histology, previous history of cancer or other concurrent malignancies, or unknown data. To identify prognostic variables, we conducted Cox regression and constructed prognostic models using five ML algorithms to predict the 5-year survival. Patient records were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
The study population comprised 1212 patients. The median patient age was 60 years, and the median tumor size was 1.9 cm. The largest racial group was white (79.5 %). Furthermore, most cases were localized (95.1%), T1 (56.2%), and N0(96.4%). The most common type of surgery performed was partial mastectomy (74.8%). Analysis of the therapeutic options revealed significantly different survival rates. While surgery + RT had a 94.9% overall 5-year survival rate, surgery alone had a rate of 91%. For surgery + CTX, the survival rate was 83.5% and 80.1% for surgery + CTX + RT. The corresponding cancer specific survival rates were 68.5%, 63.5%, 75%, and 70.8%, respectively. The ML models demonstrated strong predictive capabilities, with random forest classifier performing the best. ML identified that the most contributing factors were age, followed by the N component of the AJCC stage and ER status.
Conclusions
ML approaches provide superior predictive performance compared with traditional statistical methods. The developed models can significantly aid personalized treatment planning and improve the clinical outcomes of patients with ACC.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
302P - Perceptions of women with HER2+ breast cancer on the risk of recurrence and disease management: Results from the ASKHER survey
Presenter: Matteo Lambertini
Session: Poster session 14
303P - Predicting quality of life trajectories in young women with breast cancer: 5-year results from a large prospective cohort
Presenter: Bryan Vaca-Cartagena
Session: Poster session 14
304P - Impact of estrogen receptor positivity for adjuvant endocrine therapy in luminal T1a/bN0M0 breast cancer: A multi-institutional retrospective observational study
Presenter: Shinsuke Sasada
Session: Poster session 14
305P - Prognosis of isolated locoregional recurrence after early breast cancer with immediate breast reconstruction surgery: A retrospective multi-institutional study
Presenter: Hirohito Seki
Session: Poster session 14
306P - Patient-reported symptoms in early breast cancer and future cardiovascular events: A province-wide administrative database study
Presenter: Edith Pituskin
Session: Poster session 14
307P - Exposure to Di-2-ethylhexyl phthalate and breast cancer incidence: A cohort study
Presenter: Lijuan Tang
Session: Poster session 14
308P - Impact of the COVID-19 (C19) pandemic on breast cancer (BC) treatment patterns in the US
Presenter: Mariana Chavez Mac Gregor
Session: Poster session 14
310P - Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer
Presenter: Sonya Reid
Session: Poster session 14
311P - Optimizing breast cancer staging: Redefining tumor size classification using big data analytics
Presenter: Bin Feng
Session: Poster session 14